Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States Meeting Abstract
| Authors: | Huntington, S. F.; Strunz-McKendry, T.; Masaquel, A. S.; Shapouri, S.; Sail, K.; Durno, N.; Mato, A. |
| Abstract Title: | Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States |
| Meeting Title: | ISPOR 2019 |
| Journal Title: | Value in Health |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 May 18-22 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 1098-3015 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2019-05-01 |
| Start Page: | S78 |
| End Page: | S79 |
| Language: | English |
| ACCESSION: | WOS:000472670100208 |
| DOI: | 10.1016/j.jval.2019.04.246 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PCN122 -- Source: Wos |
